Literature DB >> 30603360

Serum total bilirubin concentration in patients with type 2 diabetes as a possible biomarker of polyvascular disease.

Takeshi Nishimura1, Masami Tanaka1, Risa Sekioka1,2, Hiroshi Itoh1.   

Abstract

AIMS: The aim of this study was to investigate the association between serum total bilirubin concentration and complicated macrovascular diseases, such as cerebrovascular disease (CBVD), cardiovascular disease (CAD), and peripheral arterial disease (PAD), in patients with type 2 diabetes.
METHODS: We performed a retrospective cross-sectional study in 674 patients with type 2 diabetes. Serum total bilirubin concentration was compared between patients with and without CBVD, CAD, and PAD. Logistic regression analyses were performed to identify risk factors for CBVD, CAD, and PAD. Associations between total bilirubin concentration and the number of complicated macrovascular diseases were analyzed.
RESULTS: Patients with CBVD and PAD showed significantly lower serum total bilirubin concentrations than did those patients without those diseases. However, the bilirubin concentration did not differ between patients with and without CAD. Total bilirubin concentration was an independent predictor of CBVD, but not of CAD or PAD. There was a statistically significant trend for a decrease in bilirubin concentration in the presence of an increasing number of macrovascular diseases.
CONCLUSION: The presence of more than one macrovascular disease, called polyvascular disease, carries a high risk for cardiovascular mortality. Serum total bilirubin concentration may be useful as a clinical biomarker of polyvascular disease.

Entities:  

Keywords:  Atherosclerosis; Cerebrovascular disease; Coronary artery disease; Peripheral arterial disease; Polyvascular disease; Total bilirubin

Year:  2017        PMID: 30603360      PMCID: PMC6224939          DOI: 10.1007/s13340-017-0337-8

Source DB:  PubMed          Journal:  Diabetol Int        ISSN: 2190-1678


  41 in total

Review 1.  Management of peripheral arterial disease (PAD). TASC Working Group. TransAtlantic Inter-Society Consensus (TASC).

Authors:  J A Dormandy; R B Rutherford
Journal:  J Vasc Surg       Date:  2000-01       Impact factor: 4.268

2.  Reproducibility of blood markers of oxidative status and endothelial function in healthy individuals.

Authors:  Pascale G A Van Hoydonck; Evert G Schouten; Elisabeth H M Temme
Journal:  Clin Chem       Date:  2003-06       Impact factor: 8.327

Review 3.  Diffuse coronary disease and atherothrombosis: a rationale for long-term therapy to prevent recurrent ischemic events.

Authors:  Deepak L Bhatt
Journal:  J Invasive Cardiol       Date:  2003-03       Impact factor: 2.022

Review 4.  Role of oxidative modifications in atherosclerosis.

Authors:  Roland Stocker; John F Keaney
Journal:  Physiol Rev       Date:  2004-10       Impact factor: 37.312

5.  3-Hydroxyanthranilic acid, one of L-tryptophan metabolites, inhibits monocyte chemoattractant protein-1 secretion and vascular cell adhesion molecule-1 expression via heme oxygenase-1 induction in human umbilical vein endothelial cells.

Authors:  Hyun-Ock Pae; Gi-Su Oh; Bok-Soo Lee; Joung-Sik Rim; Young-Myeong Kim; Hun-Taeg Chung
Journal:  Atherosclerosis       Date:  2005-10-24       Impact factor: 5.162

6.  Peripheral arterial disease detection, awareness, and treatment in primary care.

Authors:  A T Hirsch; M H Criqui; D Treat-Jacobson; J G Regensteiner; M A Creager; J W Olin; S H Krook; D B Hunninghake; A J Comerota; M E Walsh; M M McDermott; W R Hiatt
Journal:  JAMA       Date:  2001-09-19       Impact factor: 56.272

7.  Bilirubin from heme oxygenase-1 attenuates vascular endothelial activation and dysfunction.

Authors:  Keiichi Kawamura; Kazunobu Ishikawa; Youichiro Wada; Satoshi Kimura; Hayato Matsumoto; Takahide Kohro; Hiroyuki Itabe; Tatsuhiko Kodama; Yukio Maruyama
Journal:  Arterioscler Thromb Vasc Biol       Date:  2004-10-21       Impact factor: 8.311

8.  Intensive lipid lowering with atorvastatin in patients with stable coronary disease.

Authors:  John C LaRosa; Scott M Grundy; David D Waters; Charles Shear; Philip Barter; Jean-Charles Fruchart; Antonio M Gotto; Heiner Greten; John J P Kastelein; James Shepherd; Nanette K Wenger
Journal:  N Engl J Med       Date:  2005-03-08       Impact factor: 91.245

Review 9.  Inflammation in atherosclerosis.

Authors:  Peter Libby
Journal:  Nature       Date:  2002 Dec 19-26       Impact factor: 49.962

10.  High prevalence of peripheral arterial disease and co-morbidity in 6880 primary care patients: cross-sectional study.

Authors:  Curt Diehm; Alexander Schuster; Jens R Allenberg; Harald Darius; Roman Haberl; Stefan Lange; David Pittrow; Berndt von Stritzky; Gerhart Tepohl; Hans-Joachim Trampisch
Journal:  Atherosclerosis       Date:  2004-01       Impact factor: 5.162

View more
  1 in total

1.  Is serum total bilirubin a predictor of prognosis in arteriosclerotic cardiovascular disease? A meta-analysis.

Authors:  Yang Lan; Huan Liu; Jinbo Liu; Hongwei Zhao; Hongyu Wang
Journal:  Medicine (Baltimore)       Date:  2019-10       Impact factor: 1.817

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.